Federal Register / Vol. 87, No. 112 / Friday, June 10, 2022 / Notices 35561 

Scientific Review Branch, Eunice 

Kennedy Shriver National Institute of 

Child Health and Human Development, 

National Institutes of Health, 6710B 

Rockledge Drive, Room 2121B, 

Bethesda, MD 20892, (301) 451–4989, 

crobbins@mail.nih.gov. The meeting is 

closed to the public. 

Dated: June 7, 2022. 

David W. Freeman, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2022–12555 Filed 6–9–22; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Diabetes and 

Digestive and Kidney Diseases; Notice 

of Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of a 

meeting of the Board of Scientific 

Counselors, NIDDK. 

The meeting will be open to the 

public as indicated below, with 

attendance limited to space available. 

Individuals who plan to attend and 

need special assistance, such as sign 

language interpretation or other 

reasonable accommodations, should 

notify the Contact Person listed below 

in advance of the meeting. 

The meeting will be closed to the 

public as indicated below in accordance 

with the provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended for the review, discussion, 

and evaluation of individual grant 

applications conducted by the 

NATIONAL INSTITUTE OF DIABETES 

AND DIGESTIVE AND KIDNEY 

DISEASES, including consideration of 

personnel qualifications and 

performance, and the competence of 

individual investigators, the disclosure 

of which would constitute a clearly 

unwarranted invasion of personal 

privacy. 

Name of Committee: Board of Scientific 

Counselors, NIDDK. 

Date: October 13–14, 2022. 

Open: October 13, 2022, 10:00 a.m. to 

10:20 a.m. 

Agenda: Introductions and Overview. 

Place: National Institutes of Health, 

Building 10, 10 Center Drive, Bethesda, MD 

20892 (Virtual Meeting). 

Closed: October 13, 2022, 10:20 a.m. to 

5:40 p.m. 

Agenda: To review and evaluate to review 

and evaluate personal qualifications and 

performance, and competence of individual 

investigators. 

Place: National Institutes of Health, 

Building 10, 10 Center Drive, Bethesda, MD 

20892 (Virtual Meeting). 

Closed: October 14, 2022, 10:00 a.m. to 

3:10 p.m. 

Agenda: To review and evaluate to review 

and evaluate personal qualifications and 

performance, and competence of individual 

investigators. 

Place: National Institutes of Health, 

Building 10, 10 Center Drive, Bethesda, MD 

20892 (Virtual Meeting). 

Contact Person: Michael W. Krause, Ph.D., 

Scientific Director, NIDDK, National Institute 

of Diabetes and Digestive and Kidney 

Diseases, National Institute of Health, 

Building 5, Room B104, Bethesda, MD 

20892–1818, (301) 402–4633, mwkrause@

helix.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.847, Diabetes, 

Endocrinology and Metabolic Research; 

93.848, Digestive Diseases and Nutrition 

Research; 93.849, Kidney Diseases, Urology 

and Hematology Research, National Institutes 

of Health, HHS) 

Miguelina Perez, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2022–12590 Filed 6–9–22; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Drug Abuse; 

Notice of Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel; NIDA– 

L Conflict SEP II. 

Date: July 1, 2022. 

Time: 1:00 p.m. to 2:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

National Institute on Drug Abuse, 301 North 

Stonestreet Avenue, Bethesda, MD 20892 

(Virtual Meeting). 

Contact Person: Gerald L. McLaughlin, 

Ph.D., Scientific Review Officer, Office of 

Extramural Policy and Review, National 

Institute on Drug Abuse, NIH, 301 North 

Stonestreet Avenue, MSC 6021, Bethesda, 

MD 20892, (301) 827–5819, gm145a@nih.gov. 

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel; NIH 

Support for Conferences and Scientific 

Meetings. 

Date: July 6, 2022. 

Time: 3:00 p.m. to 4:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

National Institute on Drug Abuse, 301 North 

Stonestreet Avenue, Bethesda, MD 20892 

(Virtual Meeting). 

Contact Person: Brian Stefan Wolff, Ph.D., 

Scientific Review Officer, Scientific Review 

Branch, Division of Extramural Research, 

National Institute on Drug Abuse, NIH, 301 

North Stonestreet Avenue, MSC 6021, 

Bethesda, MD 20892, (301) 480–1448, 

brian.wolff@nih.gov. 

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel; CuttingEdge Basic Research Awards (CEBRA). 

Date: July 15, 2022. 

Time: 10:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

National Institute on Drug Abuse, 301 North 

Stonestreet Avenue, Bethesda, MD 20892 

(Virtual Meeting). 

Contact Person: Sheila Pirooznia, Ph.D., 

Scientific Review Officer, Scientific Review 

Branch, Division of Extramural Review, 

National Institute on Drug Abuse, NIH, 301 

North Stonestreet Avenue, MSC 6021, 

Bethesda, MD 20892, (301) 496–9350, 

sheila.pirooznia@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.277, Drug Abuse Scientist 

Development Award for Clinicians, Scientist 

Development Awards, and Research Scientist 

Awards; 93.278, Drug Abuse National 

Research Service Awards for Research 

Training; 93.279, Drug Abuse and Addiction 

Research Programs, National Institutes of 

Health, HHS) 

Dated: June 6, 2022. 

Tyeshia M. Roberson-Curtis, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2022–12486 Filed 6–9–22; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Notice of 

Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 


jspears on DSK121TN23PROD with NOTICES1